|
Biological Activity:
Small molecule survivin suppresant or inhibitor; YM155 suppressed expression of survivin and induced apoptosis in p53-deficient human HRPC cell lines at 10 nmol/L.
References:
A Kita et al. Survivin suppressant: a promising target for cancer therapy and pharmacological profiles of YM155. Nippon Yakurigaku Zasshi 2010, 136(4), 198-203.
T Iwasa et al. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br. J. Cancer 2010, 103(1),
36-42.
T Nakahara et al. YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts. Cancer Res. 2007, 67, 8014-8021. [online]
R Gonzalez et al. A phase II study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 2007, 25(18S), 8538. [online]
T Satoh et al. Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors. Clin. Cancer Res. 2009, 15, 3872. [online]
Chemical Name: 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide
| 
